Bone loss after menopause is real, but the safest first question is not "Should I take hormone replacement therapy for my bones?"
The safer first question is: am I due for screening, do I already have a fracture-risk signal, and is this prevention or treatment?
The U.S. Preventive Services Task Force recommends screening women age 65 or older for osteoporosis to prevent fractures. It also recommends screening postmenopausal women younger than 65 when they have 1 or more risk factors and clinical risk assessment shows increased fracture risk. [1] [6]
That distinction matters. A lower-risk 52-year-old with no fracture history may need a future screening plan, resistance training, nutrition review, and fall-prevention basics. A 58-year-old with a low-trauma wrist fracture, long-term steroid exposure, height loss, or a bone-density scan T-score in the osteoporosis range is in a different category.
The short answer: screen first, then choose the category
Bone density after menopause has three separate decisions.
| Decision | What it answers | Why it changes the next step |
|---|---|---|
| Screening | Should I have bone-density testing now? | U.S. Preventive Services Task Force uses age and risk to decide who should be screened. [1] |
| Risk stratification | Do I have osteopenia, osteoporosis, prior fracture, or high FRAX risk? | A bone-density scan result plus clinical risk can change whether lifestyle alone is enough. [2] |
| Treatment selection | Is this prevention, menopause-symptom care, or osteoporosis treatment? | hormone replacement therapy, bisphosphonates, denosumab, anabolic therapy, calcium/vitamin D, and fall prevention do different jobs. [2] [3] [4] |
The practical mistake is collapsing all three into one yes-or-no hormone replacement therapy decision.
Who should get screened?
U.S. Preventive Services Task Force gives the cleanest screening anchor.
| Situation | Screening implication | What to ask |
|---|---|---|
| Woman age 65 or older | U.S. Preventive Services Task Force recommends osteoporosis screening to prevent fractures. [1] | Should I have central bone-density scan of hip and spine, and how will fracture risk be calculated? |
| Postmenopausal and younger than 65 with risk factors | U.S. Preventive Services Task Force recommends screening when clinical risk assessment estimates increased fracture risk. [1] | Which risk tool are we using, and what risk factors changed the timing? |
| Low body weight, parental hip fracture, cigarette smoking, or excess alcohol | U.S. Preventive Services Task Force names these as risk factors in the under-65 screening approach. [1] | Do these push me into early screening? |
| Long-term steroids, diabetes treated with insulin, or other bone-loss conditions | U.S. Preventive Services Task Force notes medical conditions and medications may increase osteoporosis and fragility-fracture risk. [1] | Do I need bone-density scan before 65 or lab review for secondary causes? |
| Adult-age fracture after 50 | The Bone Health and Osteoporosis Foundation describes a new fracture in an adult 50 or older as a signal of elevated future fracture risk. [2] | Should this be treated as a sentinel fracture-risk event, even if it felt like an accident? |
| Early menopause or ovary removal | Less estrogen exposure can raise bone-risk concern. | Should screening or hormone-replacement timing change because menopause happened early or abruptly? |
Bone-density scan is the usual screening test. U.S. Preventive Services Task Force describes central bone-density scan at the total hip, femoral neck, or lumbar spine as the most commonly used bone measurement test for screening; it correlates with bone strength and fracture outcomes and uses low radiation doses. [1]
This is also squarely within midlife gynecology care. American College of Obstetricians and Gynecologists has a clinical practice guideline focused on osteoporosis prevention, screening, and diagnosis, which is why bone density should be part of menopause risk review rather than treated as a separate aging topic. [5]
What bone-density scan and FRAX results actually mean
A bone-density scan gives bone mineral density, but fracture risk is not just a density number.
The Bone Health and Osteoporosis Foundation clinician guide defines osteoporosis by bone mineral density at the hip or lumbar spine at or below a T-score of -2.5. It also emphasizes that most fractures occur in people whose T-scores are better than -2.5 because falls, age, frailty, prior fracture, and bone quality also matter. [2]
| Finding | What it usually means | Why it matters |
|---|---|---|
| Normal bone mineral density | Bone density is not in the osteopenia or osteoporosis range. | This usually supports prevention and future timing, unless fracture or secondary-risk history changes the picture. |
| Osteopenia | T-score between -1.0 and -2.5. | This is not automatically a medication decision; FRAX and clinical context matter. [2] |
| Osteoporosis-range bone-density scan | T-score at or below -2.5 at key sites. | BHOF lists this as a pharmacologic-treatment threshold for primary fracture prevention. [2] |
| Osteopenia plus high FRAX | BHOF uses 10-year hip fracture risk at least 3% or major osteoporotic fracture risk at least 20% as a treatment threshold. [2] | Someone can need treatment without a T-score below -2.5. |
| Hip or vertebral fracture | BHOF supports treatment regardless of bone mineral density. [2] | A fracture can diagnose a high-risk state even before the scan looks severe. |
| Multiple fractures or very high risk | Endocrine Society separates high risk from very high risk. [3] | Very high-risk patients may need anabolic therapy before antiresorptive therapy. |
FRAX is useful, but it has limits. U.S. Preventive Services Task Force notes that risk tools can help decide screening, and BHOF notes FRAX limitations, including that falls, frailty, some secondary causes, dose-response effects, and lumbar-spine bone mineral density are not fully captured. [1] [2]
That is the reason a "borderline" bone-density scan report should not be read in isolation. The useful question is what the number means next to fracture history, falls, medicines, family history, body weight, kidney function, thyroid dosing, cancer treatments, and symptoms.
Where HRT fits, and where it does not
Hormone therapy can be bone-protective. It is not a universal osteoporosis plan.
The 2022 Menopause Society hormone-therapy statement says hormone therapy prevents bone loss and fracture, and that the benefit-risk ratio is generally more favorable for symptomatic women younger than 60 or within 10 years of menopause onset who have no contraindications. It also emphasizes that risks differ by type, dose, route, duration, timing, and whether a progestogen is used. [4]
The Endocrine Society guideline is narrower for fracture prevention: it suggests menopausal hormone therapy for some postmenopausal women at high fracture risk when they are under 60 or less than 10 years past menopause, have low deep vein thrombosis risk, have bothersome vasomotor or other climacteric symptoms, have no contraindications, no prior myocardial infarction or stroke, no breast cancer, and when bisphosphonates or denosumab are not appropriate. [3]
| Scenario | hormone replacement therapy role | Better framing |
|---|---|---|
| Bothersome hot flashes near menopause plus bone-loss prevention need | May be part of a symptom-and-prevention plan if risks fit. [4] | Decide through hormone replacement therapy eligibility, uterus status, route, dose, timing, and contraindications. |
| Main issue is osteoporosis-range bone-density scan | hormone replacement therapy is usually not the whole plan. | Discuss osteoporosis-specific therapy and fracture-risk reduction. [2] [3] |
| Prior hip or vertebral fracture | Do not reduce this to symptom treatment. | BHOF supports pharmacologic treatment regardless of bone mineral density. [2] |
| High clot, stroke, breast-cancer, liver, or unexplained bleeding risk | hormone replacement therapy may be a poor fit or need specialist review. | Separate bone protection from hormone eligibility. |
| Starting systemic hormone replacement therapy after age 60 or more than 10 years from menopause onset | Benefit-risk usually becomes less favorable. [4] | Ask whether a nonhormonal osteoporosis plan is safer. |
This is also why "natural estrogen is better for bones" is too vague to be useful. The decision is not estrogen versus no estrogen. It is symptom burden, fracture risk, contraindications, route, dose, age, time since menopause, uterus status, and whether osteoporosis-specific medication is indicated.
Who this fits, and who should avoid waiting
This page is the best fit if you are trying to decide whether bone density after menopause needs screening, hormone replacement therapy discussion, or an osteoporosis-treatment review.
It is not a fit for delaying care after a fracture, new spinal pain, major height loss, or symptoms that could reflect a vertebral compression fracture. It is also not a fit for using calcium, vitamin D, collagen, strength training, or hormone replacement therapy as a substitute for osteoporosis medication when fracture risk is already high.
The evidence is limited in a practical way: screening guidelines can say who should be tested, and treatment guidelines can define common thresholds, but they cannot choose the right drug or hormone route without the full clinical picture. Kidney function, esophageal disease, dental procedures, falls, cancer history, clot risk, breast-cancer history, prior stroke or heart attack, medications, and personal preferences can change the safest plan. [2] [3] [4]
Red flags and higher-risk patterns
Do not treat these as routine menopause bone concerns:
| Pattern | Why it matters |
|---|---|
| Any low-trauma fracture after age 50 | BHOF describes a new fracture in an adult 50 or older as a sentinel event for elevated future fracture risk. [2] |
| Hip or spine fracture | BHOF supports treatment regardless of bone mineral density. [2] |
| Sudden back pain, height loss, or new spinal curvature | Vertebral fractures can be silent or under-recognized and can raise future fracture risk. [2] |
| Long-term glucocorticoids, aromatase inhibitors, cancer therapy, organ transplant medicines, or thyroid over-treatment | Medication-related bone loss can change screening timing and treatment choice. |
| Early menopause, premature ovarian insufficiency, or removal of both ovaries before the usual menopause age | Bone protection may need earlier review. |
| Frequent falls, frailty, neuropathy, vision problems, sedating medicines, or balance problems | Fracture risk may be high even when bone density is not the only issue. |
| Very low body weight, smoking, heavy alcohol use, parental hip fracture, or rheumatoid arthritis | These risk factors can move someone into earlier screening or higher-risk review. [1] [2] |
Red flags do not mean the answer is always medication. They mean the plan should be based on fracture risk, not reassurance.
What to ask a clinician
Ask questions that force the right category:
- Do I meet U.S. Preventive Services Task Force screening criteria now, or should I wait until 65?
- Which risk factors changed my screening timing before 65?
- Should I have central bone-density scan at hip and spine, and will FRAX be calculated with or without bone mineral density?
- Does my result show normal bone mineral density, osteopenia, osteoporosis, or a fracture-risk threshold that changes treatment?
- Do I need labs for secondary causes, such as thyroid over-treatment, vitamin D deficiency, kidney disease, calcium problems, celiac disease, or medication-related bone loss?
- Is hormone therapy being considered for hot flashes with bone prevention as a secondary benefit, or am I being treated for osteoporosis?
- If osteoporosis medication is recommended, why this option: oral bisphosphonate, IV bisphosphonate, denosumab, anabolic therapy, romosozumab, raloxifene, or another plan?
- What would trigger repeat bone-density scan: a new fracture, a medication start, a low baseline T-score, or a 1-to-3-year monitoring interval because risk is high?
Bottom line
After menopause, bone density belongs in a fracture-risk review.
Start with screening: age 65 or older, or younger than 65 with risk factors and increased risk by clinical assessment. Then interpret bone-density scan and FRAX in context. Hormone replacement therapy can be useful bone-loss prevention for selected women, especially when menopause symptoms and timing also fit, but established osteoporosis, prior fragility fracture, or high fracture risk usually needs an osteoporosis-specific plan.
Related reading:
- Hormone Therapy After Menopause.
- Starting hormone replacement therapy After 60.
- Transdermal vs Oral Estrogen.
- Early Menopause Before 45.
- Bioidentical Hormone Replacement Therapy: FDA-Approved vs Compounded.
References
[1] USPSTF. Osteoporosis to Prevent Fractures: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
[2] LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102. doi:10.1007/s00198-021-05900-y https://pubmed.ncbi.nlm.nih.gov/35478046/
[3] Endocrine Society. Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources. https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women
[4] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[5] Osteoporosis Prevention, Screening, and Diagnosis: ACOG Clinical Practice Guideline No. 1. Obstet Gynecol. 2021;138(3):494-506. doi:10.1097/aog.0000000000004514 https://pubmed.ncbi.nlm.nih.gov/34412075/
[6] US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2025;333(6):498-508. doi:10.1001/jama.2024.27154 https://pubmed.ncbi.nlm.nih.gov/39808425/